logo
Plus   Neg
Share
Email

Bristol-Myers: FDA To Review BLA For Liso-cel - Quick Facts

Bristol-Myers Squibb Company (BMY) announced the U.S. FDA has accepted for Priority Review its Biologics License Application for lisocabtagene maraleucel, or liso-cel, for adult patients with Relapsed or Refractory Large B-Cell Lymphoma. Liso-cel is an investigational compound that is not approved for use in any country.

Liso-cel was previously granted Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations by the FDA for R/R aggressive large B-cell non-Hodgkin lymphoma and Priority Medicines (PRIME) scheme by the European Medicines Agency for R/R diffuse large B-cell lymphoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lowe's (LOW) is temporarily increasing wages of its employees. The latest move by the hardware retailer is to help its employees cope with the economical effects caused by the ongoing COVID-19 pandemic. The company has hiked salary by $2 per hour for all full-time, part-time, and seasonal hourly associates,... Amazon.com Inc. (AMZN) Founder and CEO Jeff Bezos is donating $100 million to food banks across the U.S. to support poor people who cannot afford food during this coronavirus crisis. Bezos made a $100 million gift to Feeding America, one of the largest U.S. nonprofit focused on food security. Feeding... Facebook on Thursday shared an update on its $100 million small-business grants program announced in March, saying that it will provide $40 million in grants to 10,000 U.S. small businesses that were impacted by the coronavirus pandemic. In March, the social media giant said it is offering $100 million in cash grants and ad credits for up to 30,000 eligible small businesses.
Follow RTT
>